trending Market Intelligence /marketintelligence/en/news-insights/trending/_lp7juji28m7LrNR84WjpA2 content esgSubNav
In This List

Hemogenyx Pharmaceuticals director to resign

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Hemogenyx Pharmaceuticals director to resign

Hemogenyx Pharmaceuticals Plc said Robin Campbell would resign as a nonexecutive director, effective Jan. 5, 2019.

London-based Hemogenyx Pharmaceuticals is a preclinical-stage biotechnology company that focuses on the discovery, development and commercialization of novel therapies and treatments for blood diseases.